#United States #New York #Class Action #Faruqi & Faruqi #BioAge Labs

Faruqi & Faruqi Issues Urgent Reminder to BioAge Investors

In a recent announcement, Faruqi & Faruqi, LLP, a prominent national securities law firm, is drawing attention to a pressing issue for investors of BioAge Labs, Inc. (NASDAQ: BIOA). The firm is investigating potential claims against the company and is urging affected parties to take note of the deadline for acting as lead plaintiffs in a federal securities class action lawsuit by March 10, 2025. This notification comes in light of critical developments concerning BioAge's clinical trials and stock performance over the past few months.

Background on BioAge and Recent Developments

BioAge Labs conducted its initial public offering (IPO) on September 27, 2024, which saw the sale of approximately 12.65 million shares priced at $18 each. However, just a short while later, in December 2024, significant setbacks began to surface. On December 6, BioAge announced the cessation of its STRIDES Phase 2 clinical trial for its investigational drug candidate azelaprag due to health concerns that arose in participants, specifically related to liver complications. This shocking news caught many by surprise, especially since prior Phase 1 studies had indicated no such issues.

As a direct result of this announcement, BioAge’s stock plummeted from $20.09 per share to as low as $4.65 within just a few days, indicating a stark loss of investor confidence and highlighting the potential severity of the situation.

Call to Action for Investors

James (Josh) Wilson, a partner at Faruqi & Faruqi, is actively encouraging investors who incurred losses of over $75,000 in BioAge to reach out and discuss their options further. The firm is not only investigating potential claims arising from the cessation of the clinical trial but is also interested in gathering information from various sources, including former employees, whistleblowers, and investors who believe they may have been misled regarding the company’s operations and stock performance.

“Your participation could be crucial in seeking justice for those affected,” Wilson stated. “We want to ensure that every investor has the opportunity to exercise their rights and explore potential claims.”

Understanding Your Rights as a Class Member

In class action lawsuits, the court appoints a lead plaintiff, typically the individual with the most substantial financial interest in the case. This role comes with responsibilities, including overseeing the litigation alongside counsel. It's important to note that if an investor chooses not to pursue the lead plaintiff role, they can still participate as an absent class member and are eligible for any filed recoveries.

Looking Ahead

With the deadline rapidly approaching on March 10, 2025, it is imperative for investors impacted during the period from September 26, 2024, to January 7, 2025, to act swiftly. Those wishing to learn more about the class action can visit Faruqi & Faruqi's class action webpage or directly contact Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).

Conclusion

Faruqi & Faruqi emphasizes the importance of this class action suit, not just for compensation but for accountability in corporate governance. As the investigation unfolds, it will be crucial for investors to stay informed and engaged, protecting their rights as stakeholders in BioAge Labs. Updates and further details on this case will be regularly provided across Faruqi & Faruqi's official communication channels.